Medtronic Artificial Pancreas Sustains Normal Glucose 42% Of The Time
This article was originally published in The Gray Sheet
Executive Summary
Medtronic/MiniMed continues to predict that its artificial pancreas technology will reach the U.S. market in five years, based on early-stage data showing the system maintains glucose levels in the near-normal range 42% of the time
You may also be interested in...
Biosensor Technology To Monitor Aging Processes Needed – NIH
The National Institute on Aging hopes to fund the development of non-invasive biosensor monitors to track the aging process, according to NIA Geriatrics Health Program Specialist Winifred Rossi
Biosensor Technology To Monitor Aging Processes Needed – NIH
The National Institute on Aging hopes to fund the development of non-invasive biosensor monitors to track the aging process, according to NIA Geriatrics Health Program Specialist Winifred Rossi
Medtronic/MiniMed Insulin Pump Paradigm Aims To Grow 80% Market Share
Medtronic/MiniMed expects to boost its 80% share of the U.S. diabetes pump market with the Paradigm Model 511 insulin infusion system. A full-scale U.S. launch was announced Feb. 18